PMV Pharmaceuticals reports 4.9% stake by Euclidean Capital

PMV Pharmaceuticals, Inc. Amendment No. 4 to a Schedule 13G/A reports beneficial ownership stakes held by Euclidean Capital and affiliated reporting persons.

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. Amendment No. 4 to a Schedule 13G/A reports beneficial ownership stakes held by Euclidean Capital and affiliated reporting persons. Euclidean Capital LLC and affiliated individuals/entities report 2,627,643 shares (representing 4.9%) of Common Stock.

The filing shows additional reported holdings: Greenland NFP B Ltd. 1,300,818 shares (2.4%), Greenland A LLC 346,884 shares (0.7%), and Symmetry Group Ltd. 247,203 shares (0.5%). The percentages are calculated using 53,331,766 shares outstanding as of May 12, 2026, as reported in the issuer's Form 10-Q.

Insights

Institutional Ownership Analyst

Large holder reports sub-5% stake; positions are disclosed as shared voting/dispositive power.

The cover pages show Euclidean Capital LLC and affiliated reporting persons hold 2,627,643 shares with shared voting and dispositive power. The filing is labeled an Amendment No. 4 to a Schedule 13G/A and formally reports percentages based on May 12, 2026.

Cash-flow treatment and any planned dispositions are not stated; subsequent filings would show trading activity if holders change positions.

Governance & Compliance Specialist

Disclosure aligns with passive-investor reporting thresholds under Schedule 13G; multiple entities are listed separately.

The filing lists multiple related Reporting Persons (Euclidean Capital, Mrs. Simons, Mr. Chhabra, Greenland entities, Symmetry Group) and quantifies shared voting/dispositive power per cover rows. Ownership percentages use the issuer's reported outstanding share count of 53,331,766 as the denominator.

Filing execution is certified by signatures dated 05/15/2026; no change-of-control or transaction consideration is disclosed.

Key Figures

Outstanding shares: 53,331,766 shares Euclidean beneficial ownership: 2,627,643 shares Euclidean ownership percent: 4.9% +3 more

6 metrics

Outstanding shares 53,331,766 shares as of May 12, 2026

Euclidean beneficial ownership 2,627,643 shares reported on Amendment No. 4 to Schedule 13G/A

Euclidean ownership percent 4.9% calculated using 53,331,766 shares outstanding as of May 12, 2026

Greenland NFP B Ltd. holding 1,300,818 shares cover page reported amount

Greenland A LLC holding 346,884 shares cover page reported amount

Symmetry Group Ltd. holding 247,203 shares cover page reported amount

Key Terms

Schedule 13G/A, Shared Dispositive Power, Beneficially owned

3 terms

Schedule 13G/A regulatory

"Amendment No. 4 to a Schedule 13G/A reports beneficial ownership."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Shared Dispositive Power financial

"Row 8 shows Shared Dispositive Power 2,627,643.00 for Euclidean Capital."

Beneficially owned regulatory

"Item 4(a) states the amount beneficially owned is set forth in row 9 of the cover pages."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Euclidean Capital report in PMVP?

Euclidean Capital and affiliated reporting persons report 2,627,643 shares, representing 4.9% of Common Stock. The percentage is calculated using 53,331,766 shares outstanding as of May 12, 2026, per the issuer's Form 10-Q.

Does the filing show who has voting power for PMVP shares?

Yes. The cover rows report voting and dispositive powers as shared rather than sole—Euclidean and affiliates show shared voting and shared dispositive power over 2,627,643 shares, consistent with joint reporting arrangements.

How many shares outstanding does PMVP report for percentage calculations?

The filing uses 53,331,766 shares outstanding as of May 12, 2026 to calculate ownership percentages. That outstanding count is cited from the issuer's Form 10-Q filed on May 12, 2026.

Which Greenland-related entities reported holdings in PMVP?

Three Greenland-related reporting persons are listed: Greenland NFP B Ltd. (1,300,818 shares, 2.4%), Greenland A LLC (346,884 shares, 0.7%), and Greenland NFP LLC (66,300 shares, 0.1%), as shown on the cover rows.

Does the Schedule 13G/A state any planned sales or purchases of PMVP shares?

No. The amendment reports current beneficial ownership amounts and voting/dispositive powers but does not disclose any planned purchases or dispositions. The filing provides ownership counts and signature certifications dated 05/15/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Euclidean Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,627,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,627,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,627,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Marilyn H. Simons

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,627,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,627,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,627,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Ashvin B. Chhabra

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,627,643.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,627,643.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,627,643.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Greenland NFP B Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,300,818.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,300,818.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,300,818.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.4 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Greenland NFP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 66,300.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 66,300.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

66,300.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Greenland A LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 346,884.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 346,884.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

346,884.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Symmetry Group Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 247,203.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 247,203.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

247,203.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Suite 301, Princeton, NJ 08540
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Stock, $0.00001 par value per share (the "Common Stock") of PMV Pharmaceuticals, Inc. (the "Issuer") are: (i) Euclidean Capital LLC ("Euclidean Capital") (ii) Marilyn H. Simons ("Mrs. Simons") (iii) Ashvin B. Chhabra ("Mr. Chhabra") (iv) Greenland A LLC (v) Greenland NFP B Ltd. (vi) Greenland NFP LLC (vii) Symmetry Group Ltd.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons (except Greenland NFP B Ltd. And Symmetry Group Ltd.) is: 149 Fifth Avenue, 14th Floor New York, NY 10010 The address of the principal business office of Greenland NFP B Ltd. and Symmetry Group Ltd. is: Level 1, Palm Grove House, Wickham's Cay 1 Road Town, Tortola VG1110 British Virgin Islands
(c)	Citizenship: Euclidean Capital: Delaware limited liability company Mrs. Simons: United States citizen Mr. Chhabra: United States citizen Greenland A LLC: Delaware limited liability company Greenland NFP B Ltd.: Share company incorporated in the British Virgin Islands Greenland NFP LLC: Delaware limited liability company Symmetry Group Ltd.: Share company incorporated in the British Virgin Islands
(d)	Title of class of securities: Common Stock, $0.00001 par value per share
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in row 9 of the cover pages to this Schedule 13G.
(b)	Percent of class: The information required by this item with respect to each Reporting Person is set forth in row 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 53,331,766 shares of Common Stock outstanding as of May 12, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by this item with respect to each Reporting Person is set forth in row 5 of the cover pages to this Schedule 13G.
	(ii) Shared power to vote or to direct the vote: The information required by this item with respect to each Reporting Person is set forth in row 6 of the cover pages to this Schedule 13G.
	(iii) Sole power to dispose or to direct the disposition of: The information required by this item with respect to each Reporting Person is set forth in row 7 of the cover pages to this Schedule 13G.
	(iv) Shared power to dispose or to direct the disposition of: The information required by this item with respect to each Reporting Person is set forth in row 8 of the cover pages to this Schedule 13G.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Euclidean Capital LLC

Signature:	/s/ Joseph Cosmai
Name/Title:	Manager
Date:	05/15/2026

Marilyn H. Simons

Signature:	/s/ Joseph Cosmai
Name/Title:	Attorney-in-Fact
Date:	05/15/2026

Ashvin B. Chhabra

Signature:	/s/ Joseph Cosmai
Name/Title:	Attorney-in-Fact
Date:	05/15/2026

Greenland NFP B Ltd.

Signature:	/s/ Joseph Cosmai
Name/Title:	Manager of Euclidean Capital LLC, its Manager
Date:	05/15/2026

Greenland NFP LLC

Signature:	/s/ Joseph Cosmai
Name/Title:	Manager of Euclidean Capital LLC, its Manager
Date:	05/15/2026

Greenland A LLC

Signature:	/s/ Joseph Cosmai
Name/Title:	Manager of Euclidean Capital LLC, its Manager
Date:	05/15/2026

Symmetry Group Ltd.

Signature:	/s/ Joseph Cosmai
Name/Title:	Vice President & Treasurer
Date:	05/15/2026